NanoValent has so far formally developed three NanoMod™ candidates: NV101, NV102 and NV103. These first NVP/NanoMod™ candidates (NV101 (Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and NV103 (Irinotecan-anti-CD99) are approaching phase 1 and validating programs in Ewing sarcoma (with NV101 and NV103) is underway. A further program in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is also envisaged with NV102.
Our technology promises to enables significant enhancement of the performance of therapeutic agents. For example, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted NanoMod™ with Doxorubicin and almost 40 fold versus conventional Doxorubicin. With NV101 the enhancement seen has been even greater, 40 fold versus commercially available Doxo-liposomes and 80 fold versus Doxorubicin. We are already seeing similar, perhaps greater, potential of enhanced power and control in other potential NV candidates as we explore new therapeutic and targeting combinations. Once we achieve basic clinical validation NanoValent will progress as a company able to apply NanoMod™ to various challenges, both in oncology and beyond.